New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Thursday, November 19, 2026

Back to the front page

From X

Kevin Mak on X

$CMPS Great article this weekend in Politico about psychedelics. There's overwhelming alignment across the government to moving these treatments forward. Given this, I really can't see COMP360 getting ensnared in the approval process, or worse, through reimbursement/REMS bureaucracy once commercialized. At current prices, I believe the market is treating CMPS as a "risky proposition" because historically, that was very true. I think that regime has changed dramatically in the last 12 months. Spend some time talking to an LLM about COMP360 vs Spravato (>$2B/year in sales). Which would you rather take? But even more importantly, Spravato has <5% market share of Treatment Resistant Depression, the other ~95% of patients are generally seeking options. Disclosure: Creek Drive and its affiliated funds holds a long position in CMPS. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information. --- The VA has led the push in Washington to advance access to psychedelic therapy. It’s involved in 20 psychedelic clinical trials and was one of the first major health care systems to roll out Spravato, an FDA-approved treatment for depression using esketamine, a chemical component found in ketamine. Ketamine — an anesthetic frequently referred to as a psychedelic due to its psychoactive effects — is currently the only psychedelic-like drug approved for medical use. Trump administration officials say they hope more will be approved soon. “We want to see the drug approved if it’s safe and effective, and the reason why is because there’s a mental health crisis,” Matt Zorn, deputy general counsel at the Health and Human Services Department, told POLITICO.

Problems at AMD (AMD)

AMD has committed up to $161.1 billion in customer equity rights and $33.1 billion in guarantees, leases and investments, while holding…

Thursday Tailwinds #15: Nov 19, 2026

India’s 236 GWh battery target boosts local electrolyte-salt makers, while Mirion’s radiation monitors and Overwatch’s passive drone…

PLOW · long

Douglas Dynamics INC

Douglas Dynamics, North America’s largest snowplow and ice-control equipment maker, holds 50-60% U.S. and 60-70% Canadian market share.

Qualstar: Initiation Report

Qualstar targets 8% revenue growth in 2027 and 12% in 2028 as AI-driven storage demand and LTO-10 replacement cycles revive tape libraries.

Sea Limited: The Next Big Bet

Sea Limited’s revenue rose 43% and adjusted EBITDA 29% in Q3 as slowing Shopee and stagnant Garena shift focus to Sea Cloud.

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

Seeking Alpha 98 of 301

X accounts we follow

Every account on this site, hand-picked.

94 accounts

Investor letters we follow

383 firms

Sectors

Ordered by how often our editor reaches for them.